

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州藥業股份有限公司

Guangzhou Pharmaceutical Company Limited

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 0874)

CHANGE OF JOINT COMPANY SECRETARY

The Board of the Company announces that Ms. Lee Mei Yi has resigned as a Joint Company Secretary of the Company with effect from 29 September 2010. The Board further announces that Mr. Pang Jianhui, the secretary of the Board of the Company, has been appointed by the Board to replace Ms. Lee Mei Yi as a Joint Company Secretary of the Company with effect from 29 September 2010.

The Board of Directors (the “Board”) of Guangzhou Pharmaceutical Company Limited (the “Company”) announces that Ms. Lee Mei Yi (“Ms. Lee”) has resigned as a Joint Company Secretary of the Company with effect from 29 September 2010. Ms. Lee confirmed that there is no disagreement with the Board and there are no other matters relating to her resignation that need to be brought to the attention of the shareholders of the Company. The Board further announces that Mr. Pang Jianhui (“Mr. Pang”), the secretary to the Board of the Company, has been appointed by the Board to replace Ms. Lee as a Joint Company Secretary of the Company with effect from 29 September 2010. Mr. Pang will be assisted by Ms. Leung Ching Han (“Ms. Leung”), the other Joint Company Secretary of the Company, to discharge his functions as a Joint Company Secretary.

Ms. Leung is an associate member of both The Institute of Chartered Secretaries and Administrators and The Hong Kong Institute of Chartered Secretaries and is a qualified person possessing the relevant professional qualifications required under Rule 8.17(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”). The Company has applied for, and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) has granted, a conditional waiver from strict compliance with the requirements under Rule 8.17 and 19A.16 of the Listing Rules for a period of three years from 7 September 2010 being the date of the conditional waiver granted by the Stock Exchange.

Mr. Pang, aged 37, is a qualified senior engineer of pharmaceutical science with over 10 years of pharmaceutical industry experience. Mr. Pang joined Guangzhou Pharmaceutical Holdings Limited (“GPHL”, which is the Company’s holding company) in 1996, and served as the Business Supervisor of GPHL’s investment Department, Business Manager of an export and import subsidiary of the Company, Business Manager and Department Manager of the Business Department of a Hong Kong subsidiary

of GPLH and Deputy Director of GPLH's Investment Department. Mr. Pang currently served as a director of Guangzhou Wang Lao Ji Pharmaceutical Co., Ltd., a director of Guangzhou Pan Gao Shou Pharmaceutical Co., Ltd., a director of Guangzhou Han Fang Modern Chinese Medicine Research and Development Co., Ltd. Mr. Pang has joined the secretarial department of the Company since early 2008 and was then appointed as the secretary of the Board on 30 July 2008.

The Board of
Guangzhou Pharmaceutical Company Limited

Guangzhou, the PRC, 29 September 2010

As at the date of this announcement, the Board comprises Mr. Yang Rongming, Mr. Li Chuyuan, Mr. Shi Shaobin and Mr. Wu Changhai as executive directors, and Mr. Liu Jinxiang, Mr. Li Shanmin, Mr. Zhang Yonghua, Mr. Wong Lung Tak Patrick and Mr. Qiu Hongzhong as independent non-executive directors.